Last updated: August 14, 2026
OLPRUVA is a branded oral suspension formulation of sodium phenylbutyrate for urea cycle disorders. The FDA approved it in December 2022, giving Acer Therapeutics and its commercial partner Eton Pharmaceuticals a differentiated product in a small rare-disease market dominated by Ravicti, Buphenyl and compounded sodium phenylbutyrate. OLPRUVA’s commercial opportunity depends on formulation conversion, reimbursement access and patient-support execution rather than expansion of the underlying drug molecule.
Public filings do not separately report OLPRUVA revenue, gross margin or patient counts. Its financial trajectory is therefore best assessed through product launch timing, Eton’s portfolio disclosures, market structure and the limitations of its intellectual-property position.
What is OLPRUVA and what disease does it treat?
OLPRUVA contains sodium phenylbutyrate, a nitrogen-scavenging agent used with dietary management for patients with urea cycle disorders, or UCDs. The product is supplied as granules that are mixed with water to form an oral suspension.
UCDs are inherited metabolic disorders that impair ammonia elimination. The addressable population is small, but treatment is chronic and medically necessary. Patients typically require long-term nitrogen-scavenging therapy, dietary protein restriction and monitoring by metabolic specialists.
The FDA label covers patients aged two months and older who cannot be adequately managed with dietary protein restriction and amino acid or nitrogen-free supplementation alone. OLPRUVA is not a curative treatment and does not replace emergency management of acute hyperammonemia.[1]
How does OLPRUVA differ from other sodium phenylbutyrate products?
The principal commercial distinction is dosage form. Earlier sodium phenylbutyrate products include tablets, capsules, powders and compounded preparations. OLPRUVA is designed to create a ready-to-administer oral suspension after mixing the granules with water.
| Product |
Active ingredient |
Dosage form |
Primary commercial position |
| OLPRUVA |
Sodium phenylbutyrate |
Granules for oral suspension |
Branded pediatric and administration-focused product |
| Buphenyl |
Sodium phenylbutyrate |
Tablets and powder |
Established branded product; generic competition |
| Generic sodium phenylbutyrate |
Sodium phenylbutyrate |
Tablets, powder or compounded forms |
Lower-cost alternative |
| Ravicti |
Glycerol phenylbutyrate |
Oral liquid |
Branded liquid alternative from Horizon Therapeutics, now part of Amgen |
OLPRUVA’s value proposition is strongest for children, patients who cannot swallow tablets and patients for whom caregivers need a standardized liquid preparation. Its weakness is that the active ingredient is old, generic and clinically familiar, which limits the ability to sustain a large formulation premium.
When did OLPRUVA receive FDA approval and lose exclusivity?
The FDA approved OLPRUVA on December 22, 2022, under the 505(b)(2) pathway.[2] The product received orphan-drug designation for UCD treatment.
The key regulatory dates are:
| Milestone |
Date or status |
| FDA approval |
December 22, 2022 |
| Approval pathway |
505(b)(2) new drug application |
| Disease area |
Urea cycle disorders |
| Orphan-drug exclusivity |
Expected to run through December 2029, subject to statutory limitations |
| Patent-based exclusivity |
Must be assessed separately from orphan exclusivity |
| Pediatric exclusivity |
No publicly confirmed six-month pediatric extension identified in the cited materials |
Orphan-drug exclusivity generally prevents FDA approval of another product for the same orphan indication for seven years, unless an exception applies, such as inability to assure sufficient supply or clinical superiority by the competing product.[3] Orphan exclusivity does not prevent approval of products with different indications, and it does not block all forms of competition from existing products or compounded preparations.
OLPRUVA’s principal regulatory protection is therefore its indication-specific orphan exclusivity, not exclusivity over sodium phenylbutyrate as a molecule.
What patents protect OLPRUVA?
OLPRUVA is based on an old active pharmaceutical ingredient. The commercial patent position is consequently more likely to involve formulation, dosage form, manufacturing and administration technology than composition-of-matter protection.
Publicly available product information does not establish a broad, long-duration patent monopoly over sodium phenylbutyrate. The relevant patent questions are:
- Whether OLPRUVA has patents listed in the FDA Orange Book.
- Whether those patents cover the granule composition, suspension properties, taste-masking system, packaging or dosing method.
- Whether a generic applicant can design around those claims.
- Whether any listed patents expire before or after orphan exclusivity ends.
A patent estate built around a formulation can delay an ANDA applicant only if the patents are listed and enforceable under the Hatch-Waxman framework. It does not automatically prevent compounded sodium phenylbutyrate or alternative approved products from remaining available.
What formulations are protected by OLPRUVA patents?
The product’s commercial differentiation is concentrated in the oral-suspension formulation. Potential claim categories include:
- Granules that disperse in water at a controlled concentration.
- Taste-masking or palatability systems.
- Particle-size and dissolution characteristics.
- Packaging configurations and dose preparation.
- Methods for administering sodium phenylbutyrate to pediatric patients.
The economic value of these claims depends on whether they cover a commercially necessary feature or merely one implementation. A generic manufacturer could target a tablet, powder, alternative suspension or different excipient system if the regulatory pathway permits.
How large is the OLPRUVA market?
The UCD market is small in patient volume but high in treatment intensity. Patients generally remain on therapy for years, creating recurring prescription demand. The market is concentrated among metabolic clinics, specialty pharmacies and a limited number of expert prescribers.
The addressable population is constrained by:
- Low disease prevalence.
- Diagnosis often occurring in infancy or childhood.
- Treatment concentration in specialist centers.
- Existing use of Buphenyl, generic sodium phenylbutyrate and Ravicti.
- Clinical switching friction for stable patients.
- Payer scrutiny of branded formulations containing an established generic active ingredient.
The commercial opportunity is therefore a share-of-therapy opportunity rather than a broad population expansion opportunity.
What drives OLPRUVA adoption?
OLPRUVA adoption is likely to come from four segments:
- Newly diagnosed pediatric patients who need a liquid or suspension formulation.
- Patients with difficulty swallowing tablets or managing powder.
- Patients whose caregivers prefer a standardized product over compounding.
- Patients switching from sodium phenylbutyrate products because of tolerability, convenience or administration burden.
The product has less leverage with patients who are stable on low-cost generic sodium phenylbutyrate or on Ravicti and whose insurance plans require step therapy.
How does OLPRUVA compare with Ravicti and Buphenyl?
Ravicti is the closest branded comparator because it provides a liquid nitrogen-scavenging therapy. Buphenyl and generic sodium phenylbutyrate represent the main price competitors.
| Factor |
OLPRUVA |
Ravicti |
Generic sodium phenylbutyrate |
| Active ingredient |
Sodium phenylbutyrate |
Glycerol phenylbutyrate |
Sodium phenylbutyrate |
| Administration |
Granules mixed with water |
Oral liquid |
Tablet, powder or compounded form |
| Brand positioning |
Administration convenience and pediatric use |
Established branded liquid therapy |
Lowest-cost option |
| Generic substitution pressure |
High because active ingredient is generic |
Lower at the product level |
Direct |
| Switching barrier |
Moderate, due to metabolic-clinic oversight |
Moderate to high |
Low for price-driven payers |
| Main commercial risk |
Payer rejection and substitution |
Price and market access |
Formulation and cost competition |
Ravicti has an established commercial base and a liquid format, but its different active ingredient and dosing characteristics create clinical and economic distinctions. OLPRUVA must establish a reason to switch rather than simply demonstrate that it works.
What is the FDA and Orange Book status of OLPRUVA?
OLPRUVA is an FDA-approved small-molecule drug, not a biologic. Biosimilar competition is therefore not applicable. Any future competing product would generally proceed through an ANDA, 505(b)(2) application or full NDA pathway, depending on formulation and clinical differences.
The Orange Book analysis should focus on:
- Listed patents associated with the approved NDA.
- Patent expiration dates.
- Pediatric exclusivity, if granted.
- Any reference-listed-drug exclusivity remaining after approval.
- The scope of the approved indication and dosage form.
A competing oral suspension may face a more complex 505(b)(2) or NDA strategy than a conventional tablet ANDA because the formulation and administration characteristics may differ. A conventional sodium phenylbutyrate tablet or powder, however, would not necessarily need to replicate OLPRUVA’s commercial presentation.
Which companies are competing with OLPRUVA?
The competitive field includes the following companies and product categories:
- Acer Therapeutics, the originator and FDA applicant associated with OLPRUVA.
- Eton Pharmaceuticals, the specialty-pharmaceutical company associated with commercial development and distribution of OLPRUVA.
- Amgen, which acquired Horizon Therapeutics and markets Ravicti.
- Generic manufacturers of sodium phenylbutyrate.
- Compounding pharmacies supplying alternative sodium phenylbutyrate preparations.
- Metabolic-disease specialists that influence treatment selection through clinical protocols.
The market is not likely to attract many new entrants because the patient population is small, clinical recruitment is difficult and reimbursement depends on specialty-pharmacy infrastructure. The more credible threat is substitution by existing products or a formulation-specific generic, not a wave of novel UCD therapies.
What is OLPRUVA’s financial trajectory?
OLPRUVA’s revenue trajectory is likely to follow a staged rare-disease launch pattern:
2022 to 2023: regulatory preparation
The FDA approval created the regulatory asset, but the product required manufacturing readiness, specialty-pharmacy contracting, payer negotiations and patient-support implementation. Revenue during this stage was likely limited or pre-commercial.
2024: initial commercial launch
The commercial opportunity began to develop through new-patient starts and conversions from other sodium phenylbutyrate formulations. Early revenue would be constrained by formulary reviews, prior authorization and gradual metabolic-clinic adoption.
2025 onward: conversion and persistence
The growth case depends on three metrics:
- New UCD diagnoses captured by the product.
- Conversion of existing sodium phenylbutyrate users.
- Persistence and refill rates among patients using OLPRUVA.
Because the underlying population is small, annual revenue can change materially with a limited number of patient wins or losses. A single high-dose patient may generate meaningful revenue, while loss of a specialist account can have a visible effect on quarterly performance.
Eton’s public reporting does not separately disclose OLPRUVA revenue. This prevents a product-level assessment of sales growth, realized price, gross-to-net discounts and contribution margin from publicly reported consolidated figures. The product’s financial contribution should therefore be evaluated through portfolio-level disclosures, launch commentary and prescription or patient data rather than inferred from company revenue alone.
How strong is the OLPRUVA patent estate?
OLPRUVA has a moderate commercial protection profile but not the profile of a newly discovered molecule.
Its strengths are:
- Seven-year orphan exclusivity for the approved UCD indication.
- A differentiated oral-suspension presentation.
- Specialist prescriber concentration.
- Chronic treatment duration.
- Potential formulation and manufacturing claims.
- Difficulty of rapidly changing therapy in medically fragile patients.
Its weaknesses are:
- Sodium phenylbutyrate is an established active ingredient.
- Generic and compounded alternatives already exist.
- Orphan exclusivity is indication-specific.
- A formulation patent may be designed around.
- Payers can require use of lower-cost alternatives.
- Product-level revenue is not separately disclosed.
The strongest barrier is likely the combination of orphan exclusivity, physician familiarity and patient-support execution. The weakest barrier is molecule-level intellectual property.
What generic entry risks exist for OLPRUVA?
Generic entry risk is structurally higher than for a novel chemical entity because sodium phenylbutyrate has been marketed for years. The principal scenarios are:
| Scenario |
Timing pressure |
Commercial effect |
| Existing generic sodium phenylbutyrate remains preferred |
Immediate |
Limits price and conversion potential |
| Generic tablet or powder gains broader coverage |
Before orphan expiry |
Reduces payer willingness to cover OLPRUVA |
| Formulation-specific ANDA is approved after patent resolution |
Patent-dependent |
Directly attacks OLPRUVA’s dosage form |
| 505(b)(2) liquid competitor enters |
Clinical and regulatory dependent |
Could compete for pediatric and swallowing-impaired patients |
| Compounding expands |
State and quality dependent |
Adds price pressure but may not match standardized presentation |
A generic competitor does not need to reproduce every commercial advantage of OLPRUVA. It only needs to offer an acceptable administration option at a lower net cost.
What patent litigation or settlement agreements affect OLPRUVA?
No major publicly reported Paragraph IV litigation or generic settlement involving OLPRUVA is established in the cited sources. The absence of reported litigation is consistent with the product’s early commercial age and small market, but it does not eliminate future challenge risk.
The most likely litigation trigger would be an ANDA applicant challenging any Orange Book-listed formulation patent. If no relevant patent is listed, a generic applicant could have a clearer path once applicable regulatory exclusivity expires.
No material licensing settlement affecting OLPRUVA’s market entry is identified in the cited materials. The commercial relationship between Acer and Eton is more relevant to launch economics than a patent settlement because it determines sales execution, supply responsibility and allocation of product economics.
What revenue exposure does OLPRUVA create for Eton and Acer?
For Eton, OLPRUVA provides exposure to a rare-disease product with recurring demand and a specialist prescriber base. The product can improve portfolio mix if it achieves premium reimbursement and strong persistence.
The financial risks are concentrated in:
- High patient-acquisition costs.
- Prior-authorization delays.
- Mandatory generic or Ravicti step therapy.
- Limited total patient population.
- Manufacturing and supply reliability.
- Gross-to-net discounts.
- Dependence on a small number of metabolic centers.
- Potential difficulty converting stable patients.
For Acer, the economic value depends on the commercial agreement with Eton, including royalties, milestones, supply economics and territorial rights. Public disclosures should be used to distinguish booked product revenue from license income, milestone proceeds and manufacturing revenue.
What is the likely OLPRUVA launch scenario?
The base case is a gradual specialty launch with moderate patient conversion and limited market expansion. OLPRUVA is more likely to become a durable niche product than a mass-market rare-disease asset.
The upside case requires:
- Strong uptake in newly diagnosed pediatric patients.
- Favorable payer coverage without mandatory generic failure.
- Demonstrated caregiver and physician preference.
- Reliable specialty-pharmacy fulfillment.
- Successful conversion from Buphenyl or compounded sodium phenylbutyrate.
- Continued protection through orphan exclusivity and defensible formulation claims.
The downside case is a reimbursed-price squeeze in which payers cover OLPRUVA only after generic sodium phenylbutyrate failure. In that scenario, OLPRUVA remains clinically relevant but produces limited commercial growth.
Key Takeaways
- OLPRUVA is a branded sodium phenylbutyrate oral suspension approved for UCDs in December 2022.
- Its main differentiation is administration convenience, particularly for pediatric and swallowing-impaired patients.
- Orphan-drug exclusivity is expected to provide indication-specific protection through December 2029.
- Sodium phenylbutyrate is an established generic molecule, so OLPRUVA lacks broad composition-of-matter protection.
- The main competitors are Ravicti, Buphenyl, generic sodium phenylbutyrate and compounded products.
- No major publicly reported Paragraph IV litigation or settlement is identified in the cited materials.
- Eton and Acer do not publicly report enough product-level data to calculate OLPRUVA revenue, margin or patient share with precision.
- The commercial outcome depends more on payer access and patient conversion than on disease-population growth.
- Generic substitution and reimbursement restrictions are the principal threats to the financial trajectory.
FAQs
Is OLPRUVA a biologic or a generic drug?
OLPRUVA is a small-molecule prescription drug containing sodium phenylbutyrate. It is not a biologic, so biosimilar approval pathways do not apply. Generic and 505(b)(2) competition are the relevant entry risks.
Is OLPRUVA the same as Buphenyl?
Both contain sodium phenylbutyrate, but OLPRUVA is supplied as granules for oral suspension, while Buphenyl is available in other dosage forms. The products may differ in administration, excipients, labeling and payer coverage.
Who markets OLPRUVA?
Acer Therapeutics developed the product, while Eton Pharmaceuticals has been associated with its commercial rollout and specialty-pharmaceutical distribution. The precise allocation of royalties, supply revenue and milestone economics depends on the applicable commercial agreement.
Can a patient switch from Ravicti to OLPRUVA?
A switch may be clinically possible, but dosing, sodium load, tolerability, dietary management and ammonia monitoring must be assessed by the treating metabolic specialist. Ravicti contains glycerol phenylbutyrate, while OLPRUVA contains sodium phenylbutyrate.
What is the biggest investment risk for OLPRUVA?
The primary investment risk is limited net market penetration. Existing generic sodium phenylbutyrate and Ravicti already address the UCD treatment market, so OLPRUVA must earn reimbursement and switching preference despite using an established active ingredient.
References
- U.S. Food and Drug Administration. (2022). OLPRUVA (sodium phenylbutyrate) oral suspension: Prescribing information.
- U.S. Food and Drug Administration. (2022). FDA approves OLPRUVA for patients with urea cycle disorders. Drugs@FDA.
- U.S. Food and Drug Administration. (2023). Orphan drug designation and exclusivity.
- Eton Pharmaceuticals, Inc. (2024). Annual report and filings. U.S. Securities and Exchange Commission.
- Acer Therapeutics Inc. (2022). OLPRUVA FDA approval and commercial development materials.
